Mangoceuticals sinks after Novo Nordisk, Lilly deny obesity drugs partnership

** Shares of telehealth platform Mangoceuticals MGRX, also known as MangoRx, reverse course to slump 22.5% to $1.35

** Had soared 35% after MGRX announced a partnership with Eli Lilly LLY and Novo Nordisk NOVO_B to sell the drugmakers' blockbuster weight-loss drugs through its platform

** Late afternoon, Novo and Lilly said they do not have a weight-loss drug partnership with Mangoceuticals

** Mangoceuticals did not respond to request for comment

** The stock is down 25.3% YTD